- Profit after tax
- Rs (7.4) mn
- EPS
- Rs (0.07)
- EPS a year earlier
- Rs (0.32)
PSX Pharmaceuticals
LIVEN Liven Pharma Limited
Latest results: FY2026 · Jun 2026
FY2026 revenue Rs 105.8 mn (-16.9%), loss Rs 31.1 mn.
Last close · 13 Nov 2026
Rs 39.19 ▲ 3.56 (+9.99%)
▼ 19.3% 1 year
- Market cap
- Rs 4.4 bn
- P/E
- —
- FY2026
- P/B
- 4.50×
- FY2026
- Sector 3.11× · higher
- Dividend yield
- 0.0%
- FY2026
- ROE
- -3.8%
- FY2026
- Sector 21.7% · lower
- EPS
- Rs -0.28
- FY2026
- Book value / share
- Rs 8.72
- FY2026
Fundamentals
LIVEN at a glance
Revenue · FY2026
Rs 105.8 mn
▼ 16.9% year on year
Profit attributable to shareholders · FY2026
-Rs 31.1 mn
EPS – basic (Rs) · FY2026
Rs -0.28
Dividend per share (Rs) · FY2026
Rs 0.00
Net margin · FY2026
-29.4%
+429.8 pts year on year
Debt to equity · FY2026
3.4%
-2.1 pts year on year
Price performance
LIVEN returns
Close Rs 39.19
13 Nov 2026
| Period | Return | Rs | vs KSE-100 |
|---|---|---|---|
| MTD Month to date | +28.1% +21.2 pts vs KSE | +8.60 | +21.2 pts KSE +6.9% |
| 3M 3 months | +11.9% +13.1 pts vs KSE | +4.16 | +13.1 pts KSE −1.2% |
| 6M 6 months | +4.8% −1.4 pts vs KSE | +1.80 | −1.4 pts KSE +6.2% |
| YTD Year to date | −24.6% −26.8 pts vs KSE | −12.78 | −26.8 pts KSE +2.2% |
| FYTD Fiscal year to date | −3.8% −2.4 pts vs KSE | −1.53 | −2.4 pts KSE −1.4% |
| 1Y 1 year | −19.3% −30.0 pts vs KSE | −9.36 | −30.0 pts KSE +10.7% |
| Long term | |||
| 3Y 3 years | +176.2% +40.3% a year −38.5 pts vs KSE | +25.00 | −38.5 pts KSE +214.7% |
| 5Y 5 years | +73.0% +11.6% a year −215.9 pts vs KSE | +16.53 | −215.9 pts KSE +288.8% |
Price return from the last close before each period; the fiscal year ends 30 June. Dividends are not included.
Liven Pharma Limited in brief
Liven Pharma Limited (LIVEN) reported revenue of Rs 105.8 mn for FY2026 (Jul 2025 – Jun 2026), down 16.9% from FY2025.
It made a loss of Rs 31.1 mn attributable to shareholders (EPS Rs -0.28), a net margin of -29.4%.
No cash dividend was declared for FY2026.
The balance sheet showed net cash of Rs 148.1 mn.
Return on equity was -3.8%.
At Rs 39.19 (close on 13 Nov 2026) the shares trade at 4.50× book value.
Scorecard vs Pharmaceuticals
14 companies- Growth
- No figure
- —
- Profitability
- Weak
- -29.4%
- Financial health
- Average
- 3.4%
- Valuation
- Loss-making
- —
- Dividends
- Below average
- 0.0%
Ratings place the company in its sector: growth (3-year revenue growth), profitability (net margin; return on equity for banks, insurers and finance companies), financial health (debt to equity, industrial companies), valuation (P/E at today's price) and dividends (yield at today's price). Five dots = top fifth. Rated within the sector when at least four companies report the figure, otherwise against all PSX companies of the same type (marked vs PSX). Information, not investment advice.
Corporate
LIVEN announcements & payouts
- Profit after tax
- Rs (31.1) mn
- EPS
- Rs (0.28)
- EPS a year earlier
- Rs (8.37)
Book closure 19 Oct – 26 Oct 2026
- Profit after tax
- Rs (5.9) mn
- EPS
- Rs (0.06)
- Profit after tax
- Rs (1.9) mn
- EPS
- Rs (0.02) -100.8%
- EPS a year earlier
- Rs 2.46
Financial highlights
LIVEN financial results
| Rs mn | FY2026 Jul 2025 – Jun 2026 | FY2025 * Jul 2024 – Jun 2025 | FY2024 * Jul 2023 – Jun 2024 | FY2023 Jul 2022 – Jun 2023 | FY2022 Jul 2021 – Jun 2022 | FY2021 * Jul 2020 – Jun 2021 | FY2020 * Jul 2019 – Jun 2020 | FY2019 Jul 2018 – Jun 2019 | FY2018 Jul 2017 – Jun 2018 | FY2017 Jul 2016 – Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 105.8 | 127.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 26.6 | 18.0 | 0.0 | 0.0 | 0.0 | (16.1) | (17.8) | (16.7) | (1.9) | (22.4) |
| Operating profit | (62.4) | (489.8) | (13.8) | (15.2) | (17.5) | (18.2) | (20.0) | (18.7) | (4.6) | (26.2) |
| Profit after tax | (31.1) | (584.5) | (11.2) | (12.3) | (14.3) | (14.6) | (16.9) | (15.2) | (56.5) | (37.6) |
| Profit attributable to shareholders | (31.1) | (584.5) | (11.2) | (12.3) | (14.3) | (14.6) | (16.9) | (15.2) | (56.5) | (37.6) |
| EPS – basic (Rs) Rs | (0.28) | (7.11) | (0.78) | (0.86) | (1.00) | (1.03) | (1.19) | (1.07) | (3.96) | (2.64) |
| Dividend per share (Rs) Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total assets | 1,216.0 | 822.9 | 119.7 | 131.5 | 144.6 | 159.6 | 174.4 | 192.3 | 176.8 | 212.9 |
| Total equity | 985.5 | 633.9 | (133.8) | (122.6) | (110.3) | (96.0) | (77.7) | (60.8) | (62.3) | 16.2 |
| Total debt | 33.4 | 34.7 | 238.5 | 237.6 | 235.4 | 233.1 | 226.3 | 224.4 | 222.6 | 165.8 |
| Net cash from operating activities | 9.0 | (1.7) | (0.9) | (2.3) | (2.3) | (6.8) | (1.9) | (1.8) | (4.8) | (5.1) |
| Capital expenditure | (29.7) | (32.8) | — | — | — | — | — | — | — | — |
| Free cash flow (operating cash flow − capex) | (20.7) | (34.6) | — | — | — | — | — | — | — | — |
| Rs mn | TTM to Jun 2026 | Q4 FY2026 Apr – Jun 2026 | Q3 FY2026 Jan – Mar 2026 | Q2 FY2026 Oct – Dec 2025 | Q1 FY2026 Jul – Sep 2025 | Q4 FY2025 Apr – Jun 2025 | Q3 FY2025 Jan – Mar 2025 | Q2 FY2025 Oct – Dec 2024 | Q1 FY2025 Jul – Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 105.8 | 13.2 | 29.2 | 54.6 | 8.8 | 6.5 | 14.8 | 17.1 | 88.9 |
| Gross profit | 26.6 | (3.7) | 8.4 | 18.0 | 3.9 | (20.1) | 3.7 | 9.5 | 24.8 |
| Operating profit | (62.4) | (36.7) | (4.9) | 10.3 | (31.1) | (612.5) | (7.3) | (9.5) | 134.5 |
| Profit after tax | (31.1) | (25.2) | (4.0) | 28.2 | (30.2) | (695.3) | (9.6) | (9.5) | 147.6 |
| Profit attributable to shareholders | (31.1) | (25.2) | (4.0) | 28.2 | (30.2) | (695.3) | (9.6) | (9.5) | 147.6 |
| EPS – basic (Rs) Rs | (0.22) | (0.17) | (0.03) | 0.25 | (0.27) | (9.14) | (0.08) | (0.08) | 1.35 |
| Dividend per share (Rs) Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total assets | 1,216.0 | 1,216.0 | 982.4 | 811.2 | 804.6 | 822.9 | 977.9 | 972.6 | 961.6 |
| Total equity | 985.5 | 985.5 | 828.0 | 631.9 | 603.7 | 633.9 | 895.9 | 904.3 | 922.6 |
| Total debt | 33.4 | 33.4 | 27.4 | 31.4 | 37.9 | 34.7 | 38.1 | 25.5 | 19.4 |
| Net cash from operating activities | 9.0 | 17.3 | (9.2) | 6.8 | (5.8) | 250.4 | (238.7) | (13.0) | (0.4) |
| Capital expenditure | (50.0) | (11.8) | (23.3) | (14.7) | (0.2) | (223.9) | (13.3) | (0.6) | — |
| Free cash flow (operating cash flow − capex) | (41.0) | 5.4 | (32.5) | (7.9) | (6.0) | 26.4 | (252.0) | (13.6) | — |
Figures in Pakistani rupees as reported by the company; costs and cash outflows in brackets. Free cash flow and book value per share are calculated by Smart Money; TTM = the latest four quarters. Updated 17 Oct 2026.
LIVEN charts
Valuation
LIVEN valuation at today's price
- Price to earnings (P/E)
- —
- EPS Rs -0.28 (FY2026)
- Price to book (P/B)
- 4.50×
- Book value Rs 8.72 (FY2026)
- Dividend yield
- 0.0%
- DPS Rs 0.00 (FY2026)
- Earnings yield
- -0.7%
- EPS ÷ price
At the closing price of Rs 39.19 on 13 Nov 2026. P/E and P/B are not shown when earnings or book value are negative.
Sector peers
LIVEN vs Pharmaceuticals companies
| Company | Market cap | P/E | P/B | Yield | ROE | 3-yr growth |
|---|---|---|---|---|---|---|
| LIVEN | Rs 4.4 bn | — | 4.50× | 0.0% | -3.8% | — |
| GLAXO | Rs 107.1 bn | 10.3× | 3.11× | 5.1% | 32.4% | 16.3% |
| ABOT | Rs 97.9 bn | 11.4× | 3.05× | 4.0% | 28.8% | 15.2% |
| HALEON | Rs 81.6 bn | 12.4× | 5.02× | 4.3% | 47.6% | 16.2% |
| HINOON | Rs 50.8 bn | 12.8× | 3.95× | 5.2% | 32.3% | 20.5% |
| AGP | Rs 43.8 bn | 11.7× | 2.92× | 5.1% | 25.9% | 26.0% |
| HPL | Rs 38.5 bn | 10.3× | 4.50× | 6.0% | 38.6% | 18.6% |
| FEROZ | Rs 15.8 bn | 16.1× | 1.19× | 1.5% | 7.6% | 27.9% |
| CPHL | Rs 14.5 bn | 18.3× | 1.34× | 0.0% | 7.3% | 4.3% |
Analyses & signals 0
Win rate — · 0 closed signals · average return —
No analyses published for LIVEN yet.
LIVEN: frequently asked questions
What is LIVEN's EPS?
Liven Pharma Limited reported basic earnings per share of Rs -0.28 for FY2026 (Jul 2025 – Jun 2026).
Does LIVEN pay dividends?
Liven Pharma Limited did not declare a cash dividend for FY2026.
What was LIVEN's revenue and profit in FY2026?
Liven Pharma Limited reported revenue of Rs 105.8 mn and profit attributable to shareholders of -Rs 31.1 mn for FY2026 (Jul 2025 – Jun 2026).
What is LIVEN's book value per share?
Liven Pharma Limited's book value per share was Rs 8.72 at the end of FY2026. The shares trade at 4.50× book value.
How has LIVEN's share price performed?
LIVEN's share price is down 24.6% year to date (KSE-100: +2.2%), down 19.3% over one year (KSE-100: +10.7%) and up 73.0% over five years (KSE-100: +288.8%), as of 13 Nov 2026. These are price returns; dividends are not included.
Information only, not investment advice.